Total Payments
$569,984
2023 Payments
$10,894
Companies
1
Transactions
29
Payment Breakdown by Category
Consulting$569,882 (100.0%)
Food & Beverage$101.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $569,882 | 27 | 100.0% |
| Food and Beverage | $101.80 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Agilent Technologies, Inc. | $569,984 | 29 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $10,894 | 5 | Agilent Technologies, Inc. ($10,894) |
| 2021 | $30,416 | 7 | Agilent Technologies, Inc. ($30,416) |
| 2020 | $227,756 | 1 | Agilent Technologies, Inc. ($227,756) |
| 2019 | $194,576 | 13 | Agilent Technologies, Inc. ($194,576) |
| 2018 | $106,288 | 2 | Agilent Technologies, Inc. ($106,288) |
| 2017 | $53.60 | 1 | Agilent Technologies, Inc. ($53.60) |
All Payment Transactions
29 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2023 | Agilent Technologies, Inc. | PD-L1 IHC 28-8 PHARMDX (Device) | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| Category: PD-1/PD-L1 inhibitors | ||||||
| 12/07/2023 | Agilent Technologies, Inc. | — | Consulting Fee | Cash or cash equivalent | $75.00 | General |
| 08/17/2023 | Agilent Technologies, Inc. | OMNIS (Device) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Immunohistochemistry (IHC) and in Situ Hybridization Platform | ||||||
| 07/20/2023 | Agilent Technologies, Inc. | OMNIS (Device) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: Immunohistochemistry (IHC) and in Situ Hybridization Platform | ||||||
| 06/21/2023 | Agilent Technologies, Inc. | OMNIS (Device) | Consulting Fee | Cash or cash equivalent | $3,093.75 | General |
| Category: Immunohistochemistry (IHC) and in Situ Hybridization Platform | ||||||
| 12/07/2021 | Agilent Technologies, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 11/10/2021 | Agilent Technologies, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 10/02/2021 | Agilent Technologies, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,712.50 | General |
| 08/16/2021 | Agilent Technologies, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,262.50 | General |
| 06/26/2021 | Agilent Technologies, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,456.25 | General |
| 04/28/2021 | Agilent Technologies, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,875.00 | General |
| 02/26/2021 | Agilent Technologies, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,809.90 | General |
| 03/19/2020 | Agilent Technologies, Inc. | — | Consulting Fee | Cash or cash equivalent | $227,756.25 | General |
| 12/18/2019 | Agilent Technologies, Inc. | PD-L1 IHC 22C3 (Device) | Consulting Fee | Cash or cash equivalent | $18,056.25 | General |
| Category: pharmDx | ||||||
| 11/17/2019 | Agilent Technologies, Inc. | PD-L1 IHC 22C3 (Device) | Consulting Fee | Cash or cash equivalent | $15,975.00 | General |
| Category: pharmDx | ||||||
| 10/23/2019 | Agilent Technologies, Inc. | PD-L1 IHC 22C3 (Device) | Consulting Fee | Cash or cash equivalent | $16,200.00 | General |
| Category: pharmDx | ||||||
| 09/08/2019 | Agilent Technologies, Inc. | PD-L1 IHC 22C3 (Device) | Consulting Fee | Cash or cash equivalent | $18,056.25 | General |
| Category: pharmDx | ||||||
| 07/19/2019 | Agilent Technologies, Inc. | PD-L1 IHC 22C3 (Device) | Consulting Fee | Cash or cash equivalent | $15,018.75 | General |
| Category: pharmDx | ||||||
| 07/03/2019 | Agilent Technologies, Inc. | PD-L1 IHC 22C3 (Device) | Consulting Fee | Cash or cash equivalent | $14,962.50 | General |
| Category: pharmDx | ||||||
| 05/31/2019 | Agilent Technologies, Inc. | PD-L1 IHC 22C3 (Device) | Consulting Fee | Cash or cash equivalent | $10,687.50 | General |
| Category: pharmDx | ||||||
| 05/01/2019 | Agilent Technologies, Inc. | PD-L1 IHC 22C3 (Device) | Consulting Fee | Cash or cash equivalent | $2,426.32 | General |
| Category: pharmDx | ||||||
| 04/13/2019 | Agilent Technologies, Inc. | PD-L1 IHC 22C3 (Device) | Consulting Fee | Cash or cash equivalent | $21,262.50 | General |
| Category: pharmDx | ||||||
| 04/01/2019 | Agilent Technologies, Inc. | PD-L1 IHC 22C3 (Device) | Consulting Fee | Cash or cash equivalent | $10,631.25 | General |
| Category: pharmDx | ||||||
| 02/27/2019 | Agilent Technologies, Inc. | PD-L1 IHC 22C3 (Device) | Consulting Fee | Cash or cash equivalent | $16,256.25 | General |
| Category: pharmDx | ||||||
| 02/01/2019 | Agilent Technologies, Inc. | PD-L1 IHC 22C3 (Device) | Consulting Fee | Cash or cash equivalent | $17,662.50 | General |
| Category: pharmDx | ||||||
About Dr. John Blaustein, MD
Dr. John Blaustein, MD is a Hematology healthcare provider based in Santa Barbara, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518025535.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Blaustein, MD has received a total of $569,984 in payments from pharmaceutical and medical device companies, with $10,894 received in 2023. These payments were reported across 29 transactions from 1 company. The most common payment nature is "Consulting Fee" ($569,882).
Ad
Practice Information
- Specialty Hematology
- Other Specialties Anatomic Pathology & Clinical Pathology
- Location Santa Barbara, CA
- Active Since 12/04/2006
- Last Updated 06/21/2024
- Taxonomy Code 207ZH0000X
- Entity Type Individual
- NPI Number 1518025535
Products in Payments
- PD-L1 IHC 22C3 (Device) $194,576
- OMNIS (Device) $6,019
- PD-L1 IHC 28-8 PHARMDX (Device) $4,800
- PD-L1 (Device) $101.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.